Overview

Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.
Phase:
Phase 3
Details
Lead Sponsor:
Sunovion
Treatments:
Anticonvulsants
Eslicarbazepine acetate